| Status | Topic selection |
| Technology type | Medicine |
| Decision | Not selected |
| Reason for decision | Not eligible for Health Technology Evaluation guidance |
| Further information | Decision makers have concluded that the clear rationale to not evaluate this product is due to it being a change to the formulation of an existing product as per section 7.1.3 of the NICE-wide Prioritisation manual and the use of levodopa in Parkinson’s disease is recommended in the current NICE Guideline NG71 – Parkinson’s disease in adults. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. |
| ID number | 8778 |
For further information on how we select topics for development, please see our page about topic selection